NASDAQ · ICUI

ICU Medical Inc.

$167.25 +$9.81 (+6.23%) 1D Market open
Charting by TradingView

Key Metrics

$3.93B
Market cap
84.92×
P/E · TTM
$2.16B
Revenue · TTM
$46.34M
Net income
EPS · TTM $1.89
Dividend yield —
Free cash flow $82.71M
Beta · 1Y 1.05
EBITDA · TTM $251.08M
Gross margin 37.9%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 29
    From its Feb 20 high, the share price fell 26%.

    Peak close $157.03 on Feb 20; trough close $115.45 on Apr 29. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -26%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$3.93B
Enterprise value—
Shares outstanding25.0M
52-wk range$107.00 – $162.85
Avg volume · 20D226.3K
Net cash —
Book value / share$86.06
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About ICU Medical Inc.
IPO dateMar 31, 1992
Employees13000

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E84.92
P/S1.82
P/FCF47.58
EV/EBITDA—
EV/Sales—
Graham №$60.47

Profitability

Gross 37.9%
Operating 2.3%
Net 2.1%
FCF 3.8%
ROE / ROIC 2.3% · —

Financial Health

Current ratio2.34
Quick ratio1.17
Debt / equity0.61
Debt / EBITDA 5.10
Net cash —
Working capital$695.34M

Cash Flow · TTM

Operating CF $167.43M
Capex −$84.72M
Free cash flow $82.71M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

$60.47 vs $161.46
Trades 2.7× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings